Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study will help provide information about how patients with burn handle two antibiotics
(ceftolozane and tazobactam) and use that information to guide dosing recommendations for
these patients. The 12 patients who complete the study will receive a single dose of 3 grams
ceftolozane/tazobactam intravenously. We will collect blood and urine samples to determine
how much of each antibiotic is in the body and urine at various times over a 24 hour period.
This information will be used with previously published information from microbiology
laboratories to perform simulations that will provide recommendations on optimal dosing
recommendations of these antibiotics in patients with burns.
Phase:
Phase 4
Details
Lead Sponsor:
Texas Tech University Health Sciences Center
Collaborators:
Merck Sharp & Dohme Corp. Parkland Health & Hospital System University of Texas, Southwestern Medical Center at Dallas
Treatments:
Ceftolozane Ceftolozane, tazobactam drug combination Cephalosporins Penicillanic Acid Tazobactam